Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
Open Access
- 22 September 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (38) , eadg0488
Abstract
Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we developed a single-cell MRD (scMRD) assay by combining flow cytometric enrichment of the targeted precursor/blast population with integrated single-cell DNA sequencing and immunophenotyping. Our scMRD assay shows high sensitivity of approximately 0.01%, deconvolutes clonal architecture, and provides clone-specific immunophenotypic data. In summary, our scMRD assay enhances MRD detection and simultaneously illuminates the clonal architecture of clonal hematopoiesis/preleukemic and leukemic cells surviving acute myeloid leukemia therapy.Keywords
This publication has 22 references indexed in Scilit:
- Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual DiseaseJournal of Clinical Oncology, 2020
- Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid LeukemiaCancer Research, 2020
- Molecular Minimal Residual Disease in Acute Myeloid LeukemiaNew England Journal of Medicine, 2018
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AMLCancer Cell, 2017
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood, 2017
- Measurable residual disease testing in acute myeloid leukaemiaLeukemia, 2017
- Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexitiesBlood Reviews, 2017
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?Journal of Clinical Oncology, 2016
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A StudyJournal of Clinical Oncology, 2013
- ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assaysJournal of Immunological Methods, 2009